Overweight and Obese Volunteers
0
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Laekna TherapeuticsChina - Shanghai
1 programLAE102 intravenous administrationPHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
MindRankMDR-001
Laekna TherapeuticsLAE102 intravenous administration
Clinical Trials (2)
Total enrollment: 291 patients across 2 trials
A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
Start: Jun 2023Est. completion: Dec 2025131 patients
Phase 1/2Recruiting
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
Start: Jun 2024Est. completion: Sep 2026160 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 291 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.